NIKKEI 225
38,703.51 +213.34 (+0.55%) HANG SENG
18,476.80 +51.84 (+0.28%) CRUDE OIL
75.56 +1.49 (+2.01%) GOLD FUTURES
2,392.00 +16.50 (+0.69%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,020.94 -671.78 (-1.21%)
DNLI Sep 2024 22.500 put
| Previous close | 3.5500 |
| Open | 3.5500 |
| Bid | 2.3500 |
| Ask | 4.9000 |
| Strike | 22.50 |
| Expiry date | 2024-09-20 |
| Day's range | 3.5500 - 3.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 310 |
ZacksWhy Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksDenali's (DNLI) Candidate Selected for FDA's START Pilot Program
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
GlobeNewswireDenali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potential for clinical benefit for a rare neurodegenerative disease and the drug sponsor’s ability to advance development towards a marketing application Participation in START is expected to facilitate and accelerate de
